Neos Therapeutics Inc.'s upsized series C financing  from $15.5 million to $18 million  along with a $20 million loan facility with Hercules Technology Growth Capital Inc. means the firm will "not only have enough money to hit the key regulatory milestones over the next 12-15 months, but to give us financial flexibility into 2016," said Victor Miller, vice president of finance.